NCT03829306View on ClinicalTrials.gov

Unraveling KAdcyla Resistance In Human Epidermal Growth Factor Receptor 2(HER2) Positive Advanced Breast Cancer (KATIA)

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

June 12, 2018

Primary Completion Date

June 21, 2022

Study Completion Date

June 21, 2022

Conditions

Advanced Breast Cancer

Trial Locations (10)

28007

Hospital General Universitario Gregorio Marañón, Madrid

28040

Hospital Universitario Fundación Jiménez Díaz, Madrid

30120

"Hospital Clínico Universitario Virgen de la Arrixaca", El Palmar

41009

Hospital Universitario Virgen Macarena, Seville

08003

Hospital del Mar, Barcelona

08025

Hospital Universitario Santa Creu i Sant Pau, Barcelona

08908

ICO L´Hospitalet, Barcelona

Unknown

Hopsital Clínico San Carlos, Madrid

Hospital Universitario Virgen de la Victoria, Málaga

Hospital Clínico Universitario de Valencia, Valencia

All Listed Sponsors

collaborator

Roche Farma, S.A

INDUSTRY

lead

Spanish Breast Cancer Research Group

OTHER

NCT03829306 - Unraveling KAdcyla Resistance In Human Epidermal Growth Factor Receptor 2(HER2) Positive Advanced Breast Cancer (KATIA) | Biotech Hunter | Biotech Hunter